AbbVie Income Taxes 2010-2024 | ABBV

AbbVie annual/quarterly income taxes history and growth rate from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
  • AbbVie income taxes for the quarter ending September 30, 2024 were $0.520B, a 202.33% increase year-over-year.
  • AbbVie income taxes for the twelve months ending September 30, 2024 were $2.064B, a 39.27% increase year-over-year.
  • AbbVie annual income taxes for 2023 were $1.377B, a 15.63% decline from 2022.
  • AbbVie annual income taxes for 2022 were $1.632B, a 13.33% increase from 2021.
  • AbbVie annual income taxes for 2021 were $1.44B, a 217.65% decline from 2020.
AbbVie Annual Income Taxes
(Millions of US $)
2023 $1,377
2022 $1,632
2021 $1,440
2020 $-1,224
2019 $544
2018 $-490
2017 $2,418
2016 $1,931
2015 $1,501
2014 $595
2013 $1,204
2012 $450
2011 $235
2010 $658
2009 $1,314
AbbVie Quarterly Income Taxes
(Millions of US $)
2024-09-30 $520
2024-06-30 $773
2024-03-31 $383
2023-12-31 $388
2023-09-30 $172
2023-06-30 $583
2023-03-31 $234
2022-12-31 $493
2022-09-30 $448
2022-06-30 $255
2022-03-31 $436
2021-12-31 $226
2021-09-30 $508
2021-06-30 $394
2021-03-31 $312
2020-12-31 $-1,545
2020-09-30 $187
2020-06-30 $46
2020-03-31 $88
2019-12-31 $273
2019-09-30 $117
2019-06-30 $66
2019-03-31 $88
2018-12-31 $-547
2018-09-30 $14
2018-06-30 $29
2018-03-31 $14
2017-12-31 $1,141
2017-09-30 $464
2017-06-30 $438
2017-03-31 $375
2016-12-31 $607
2016-09-30 $416
2016-06-30 $486
2016-03-31 $422
2015-12-31 $407
2015-09-30 $408
2015-06-30 $312
2015-03-31 $374
2014-12-31 $-227
2014-09-30 $181
2014-06-30 $335
2014-03-31 $306
2013-12-31 $311
2013-09-30 $322
2013-06-30 $300
2013-03-31 $271
2012-12-31 $173
2012-09-30 $19
2012-06-30 $135
2012-03-31 $123
2011-12-31 $100
2011-09-30 $0
2011-06-30 $0
2011-03-31 $135
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $308.242B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $790.248B 81.85
Novo Nordisk (NVO) Denmark $489.545B 35.30
Johnson & Johnson (JNJ) United States $373.278B 15.14
Merck (MRK) United States $254.810B 16.93
Novartis AG (NVS) Switzerland $215.989B 14.36
AstraZeneca (AZN) United Kingdom $200.887B 17.90
Pfizer (PFE) United States $148.702B 10.17
Sanofi (SNY) $128.465B 11.64
Innoviva (INVA) United States $1.259B 10.48